When patients start tirzepatide (Zepbound) for obesity, the number on the scale is usually the most visible outcome. But obesity treatment is ultimately about health, not simply weight. A newly published analysis from the SURMOUNT clinical-trial program asks a useful question: how often do patients improve several important cardiometabolic measures at the same time? What
